Form 4: Cue Biopharma Director, Peter Kiener, Awarded Stock Options

Peter Kiener, a director of Cue Biopharma, Inc., was granted stock options to purchase 24,400 shares of common stock on January 2, 2025.

Summary

• On January 3, 2025, a Form 4 filing was submitted to the SEC, reporting a change in beneficial ownership for Peter A Kiener, a director of Cue Biopharma, Inc.
• Kiener was granted a stock option to purchase 24,400 shares of Cue Biopharma's common stock on January 2, 2025.
• The exercise price of the stock option is $1.09 per share.
• The options vest in two tranches: 50% on the six-month anniversary of the grant date and the remaining 50% on the first anniversary of the grant date.
• The stock options expire on January 1, 2035.
• Following the transaction, Kiener directly owns 24,400 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it does indicate confidence in the company's future prospects and aligns the director's interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 50% after six months and 50% after one year is fairly typical for director stock option grants.
• Comparing the size of the grant to similar companies would require analyzing their director compensation policies and equity ownership structures.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with increasing shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates